myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

2021 March for Marrow California - Virtual Walk and 5K

Help us continue to support the patients served by AAMDSIF by registering to run in our 2021 Virtual Walk and 5K or simply by donating. We look forward to walking and running with you the week of April 24 - May 1, 2021, and continuing the celebration of the brave patients and families that are fighting

Event Date: 
Fri, 04/23/2021 - 8:00pm (EDT) to Fri, 04/30/2021 - 8:00pm (EDT)
Community Event Type: 

Virtual March for Marrow 5K Run & Walk Washington DC 2021

Patients, family members, friends and advocates, sign up, tell your story, create a team, and set a goal to support AAMDSIF!

Anywhere you and your friends choose to, walk, run, cycle – in a park, through your neighborhood, or on a treadmill – anytime leading up to or during the day of the 24th.

Event Date: 
Sun, 10/24/2021 - 10:00am (EDT)
Community Event Type: 

Eunice Wang, MD

Wang, Eunice
Chief of Leukemia Service
Roswell Park Comprehensive Cancer Center

Dr. Eunice Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. Dr. Wang joined the Roswell Park faculty in 2003 and was appointed to the Leukemia Service of the Department of Medicine. She earned her medical degree from the Keck School of Medicine, University of Southern California and completed residency training in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT in 1999. From 1999 to 2003, she completed a clinical hematology-oncology and research fellowship at Memorial Sloan Kettering Cancer Center in New York, NY.

Dr. Swapna Thota

Thota, Swapna
Assistant Professor of Medicine
University of Tennessee

As a physician caring for patients with acute leukemias and related disorders, I have a sustained focus on translational research in hematologic malignancies. Genomic sequencing technology revolutionized our understanding of cancer biology. My research focuses on exploring the dynamic changes of tumor immune microenvironment with clonal evolution of myeloid malignancies. Targeting inflammaging of

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib in treating patients with FLT3-mutated

Share with addtoany.com.